Precision BioSciences (DTIL)
NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Price & Analysis

524 Followers

DTIL Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.80 - $3.44
Previous Close$0.85
Volume736.39K
Average Volume (3M)609.74K
Market Cap
$94.60M
Enterprise Value-$67.94M
Total Cash (Recent Filing)$189.58M
Total Debt (Recent Filing)$27.04M
Price to Earnings (P/E)-0.6
Beta1.63
May 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding110,958,955
10 Day Avg. Volume647,338
30 Day Avg. Volume609,741
Standard Deviation0.35
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.60
Price to Sales (P/S)9.34
Price to Cash Flow (P/CF)521.80
P/FCF Ratio-5.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.71
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.67
Forecast
Price Target Upside1135.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

DTIL FAQ

What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $0.80 and its highest was $3.44 in the past 12 months.
    What is Precision BioSciences’s market cap?
    Currently, no data Available
    When is Precision BioSciences’s upcoming earnings report date?
    Precision BioSciences’s upcoming earnings report date is May 10, 2023 which is in 49 days.
      How were Precision BioSciences’s earnings last quarter?
      Precision BioSciences released its earnings results on Mar 09, 2023. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.058.
        Is Precision BioSciences overvalued?
        According to Wall Street analysts Precision BioSciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Precision BioSciences pay dividends?
          Precision BioSciences does not currently pay dividends.
          What is Precision BioSciences’s EPS estimate?
          Precision BioSciences’s EPS estimate is -$0.24.
            How many shares outstanding does Precision BioSciences have?
            Precision BioSciences has 111,295,720 shares outstanding.
              What happened to Precision BioSciences’s price movement after its last earnings report?
              Precision BioSciences reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went down -11.304%.
                Which hedge fund is a major shareholder of Precision BioSciences?
                Among the largest hedge funds holding Precision BioSciences’s share is Caxton Associates LP. It holds Precision BioSciences’s shares valued at N/A.

                  ---

                  Precision BioSciences Stock Smart Score

                  The Precision BioSciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Precision BioSciences

                  Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Merrimack Pharmaceuticals
                  Tenaya Therapeutics
                  Oric Pharmaceuticals
                  Anixa Biosciences
                  Alaunos Therapeutics

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis